Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Humate-P® No Longer Requires Refrigeration
 

The U.S. Food and Drug Administration (FDA) recently approved revised storage conditions for Humate-P®, a plasma-derived factor VIII/von Willebrand factor product used in the treatment and prevention of bleeds in patients with hemophilia and von Willebrand disease. Until now, Humate-P®, which is manufactured by CSL Behring, needed to be maintained at colder, refrigerated temperatures. With the new approval, it can now be kept safely for up to two years at 77 degrees Fahrenheit.

“The change in storage conditions will help patients, their families and treating physicians better manage the product, especially as part of medically supervised home treatment programs,” said Jesse L. Goodman, MD, MPH, director of the FDA’s Center for Biologics Evaluation and Research.

Source: FDA news release dated October 19, 2007